Company Overview
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Why Investors Should Care
Revenue has grown at a 21.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $502.73M (+27.8% YoY); net profit $-60.61M.
- Trailing 12 Months Year-on-year growth — revenue +41.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 21.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 21.80% |
| 1 Year: | 41.20% |
Stock Price Performance
| 1 Year: | +15.67% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 21.8% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TOI TOI R2KPHARMA | 6.20 | -17.71 | $619.89M | 0.00% | -38.51% | - | 21.80% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 48.58M | 49.84M | 52.27M | 55.16M | 60.92M | 64.98M | 76.19M | 80.22M | 82.03M | 94.67M | 98.58M | 99.90M | 104.41M | 119.80M | 136.56M | 147.44M |
| Operating Income | -2.30K | -87.77K | -194.56K | -198.48K | -1.75M | -1.12M | -2.16M | -18.47M | -18.30M | -20.10M | -32.87M | -14.94M | -13.93M | -17.97M | -16.36M | -13.85M | -9.91M | -11.21M | -8.05M | -6.51M |
| Net Income | -2.30K | -776.84K | -2.62M | -2.42M | -996.00K | 3.21M | -2.98M | 19.29M | -5.45M | -2.67M | -30.00M | -16.90M | -17.42M | -19.89M | -15.48M | -16.11M | -19.59M | -17.01M | -16.50M | -2.49M |
| Diluted EPS | - | - | - | - | -0.02 | 0.05 | -0.05 | 0.21 | -0.06 | -0.17 | -0.33 | -0.19 | -0.19 | -0.22 | -0.17 | -0.18 | -0.21 | -0.15 | -0.14 | -0.02 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 187.51M | 203.00M | 252.48M | 324.24M | 393.41M | 502.73M |
| Operating Income | -8.20M | -45.86M | -81.95M | -77.02M | -60.12M | -36.08M |
| Net Income | -14.32M | -10.93M | 152.00K | -83.07M | -64.66M | -60.61M |
| Diluted EPS | -0.24 | -0.16 | -0.21 | -0.92 | -0.71 | -0.54 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 50.00K | 65.69M | - | 261.67M | 209.24M | 172.72M | 164.66M |
| Current Assets | - | - | - | - | 130.42M | 143.49M | 112.42M | 112.75M |
| Cash & Equivalents | - | - | 900.00K | - | 14.01M | 33.49M | 49.67M | 33.56M |
| Inventory | - | - | - | - | 9.26M | 13.68M | 10.04M | 16.88M |
| Receivables | - | - | - | - | 39.82M | 42.36M | 48.34M | 59.00M |
| Total Liabilities | - | 27.30K | 37.59M | - | 138.49M | 152.22M | 169.13M | 180.38M |
| Current Liabilities | - | 27.30K | 28.61M | - | 29.72M | 34.79M | 52.22M | 70.96M |
| Long Term Debt | - | - | 6.56M | - | 80.62M | 86.83M | 93.13M | 77.40M |
| Total Debt | - | - | - | - | 108.18M | 119.67M | 123.15M | 103.69M |
| Total Equity | 0 | 42.22M | 28.10M | - | 123.17M | 57.02M | 3.59M | -15.72M |
| Shares Outstanding | - | - | - | - | 73.27M | 75.88M | 77.47M | 100.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 508.00K | -32.68M | -61.76M | -36.31M | -26.54M | -24.59M |
| Investing Cash Flow | -8.84M | -12.15M | -131.61M | 62.64M | 46.21M | -3.07M |
| Financing Cash Flow | 11.89M | 154.01M | 92.21M | -6.85M | -3.49M | 11.56M |
| Capital Expenditure | -1.19M | -2.85M | -5.53M | -4.57M | -3.79M | -3.20M |
| Free Cash Flow | -686.00K | -35.53M | -67.28M | -40.88M | -30.33M | -27.79M |
| Share Buybacks | - | 0 | 9.00M | 1.02M | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -4.4% | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Net Margin % | -7.6% | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| ROE % | -51.0% | - | 0.1% | -145.7% | -1,801.7% | 385.5% |
| ROCE % | -22.1% | - | -35.3% | -44.1% | -49.9% | -38.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TOI
Topicus.com Inc. (TOI.V) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE1hNnpoeFRYSkRqTjRxM1A4X25tQnhUdWNpUlJOZVl5MkUwQkFnZHFTenQtRTI0cUJ2RDR3bUJQQWIzcjBhdDhzRzBzc3FqcXpTSGtB?oc=5" target="_blank">Topicus.com Inc. (TOI.V) Stock Price, News, Quote & His…
TOI Stock Price and Chart — TSXV:TOI - TradingView
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE56NXZOM280TmJRdVhNVnJyRGJINHFGMU9tcGtGTnNtS0dSTlAtN01UalozOVZ0eGRqREJNQ2dmT3pad0Jmb3ZfbTZYWVFYWldNcVlYQ2dmRFE?oc=5" target="_blank">TOI Stock Price and Chart — TSXV:TOI</a> &n…
Topicus.com Inc. (TSX:TOI): What Could Move This Stock Next on the Canadian Market? - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPakdZekVRbzNPRHJxMFVJOUFoNlNTS0ViUXFueVB3WjUyOHRfVHYwZWNoa09xdDhyNWpoNUhadlZVaEZSbnJ3NU5QV3B3ejNEMzRpZFBuTEl6LXJQWDNCX3cyUXdGUVJqdEtNSENJbWxxZERUTDBsT0gtakZYR0ZJeGd2WGFNbU9vY056SF…
What Topicus.com (TSXV:TOI)'s CEO Transition to Ramon Zanders Means For Shareholders - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNenM3akw5T2E1d3JqTlVPYWZfa1pvRnpkUml6S19wSFN1WXdiNTZiRU9uX1NLMGpOaFN1R2tkdUc5RW4zRUdCVWNNZklMazFzTVBhakV5aDJUODNuTklKeTl3UzdTVjlVWjRUMThCbk43bWU0aDJERjFKZlgzdHhJYm9nbWdrcVpoNlRGZk…
Tesla’s flying car: More stock price booster than for your garage? - The Times of India
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOeUFOY3JyWm1JMDRfUXlMR09Yc2NnQnl3OHdUZUJCSG5aenJjVVd3UmoxWnlYTjZWdTlEdVMxbEZZZ0x1Vy1MaDg3ZXpTQ2dHV3lJQzk2NFpLN0FSbDN1d2lZUms0cXpfVkNPZHlRTUhjTTNsZjYzdkJObWwxWHpEQ242bWR3bklJVVVaaj…
Topicus: The Bottom Is Where It Begins (TSXV:TOI:CA) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQZ1NlNW5uNEw0QlFJX2dRcXZ4R3Iydkl3UktKc0ZDZjYzbk9wV0plZy11dWh6ZnRpQTIzU2dmbXRJSEJTcjlGeE1rM0NaX2ZmOFlJSmZaRGt5RkV6RjBIMXdPenl5WFVLWktKUkluR0hfaUVxc1dGTHdXZnRXSEowd2tsU0pCWGNXUnJrYz…
TOI — Frequently Asked Questions
What is the current share price of TOI?
As of 2026-10-23 16:27 PDT, TOI trades at $6.20 on NasdaqCM. Its 52-week range is $4.99 to $6.41.
What is the market capitalisation of TOI?
TOI has a market capitalisation of $619.89M on NasdaqCM.
What is the P/E ratio of TOI?
TOI trades at a trailing price-to-earnings (P/E) ratio of -17.71. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -31.47.
Is TOI a good stock to buy?
This page provides a data-driven analysis of TOI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.